Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Thomas Herzog, MD, discusses the application of the PRIMA and PAOLA results in clinical practice

Dr. Herzog, Professor of Obstetrics & Gynecology, University of Cincinnati Cancer Institute, discusses the application of the PRIMA and PAOLA results in clinical practice.

Tags: Cancer Research Clinical TrialsOvarianPipeline (Phase 1-3, Pharmacology, Clinical Trials, Statistics)

Published: 25 August 2020

Recent Videos: Pipeline (Phase 1-3, Pharmacology, Clinical Trials, Statistics)

video

Thomas Herzog, MD, discusses the application of the PRIMA and PAOLA results in clinical practice

Dr. Herzog, Professor of Obstetrics & Gynecology, University of Cincinnati Cancer Institute, discusses the application of the PRIMA and PAOLA ...

video

Thomas Herzog, MD, explains the importance of "weights and plates" in the PRIMA clinical trial

Dr. Herzog, Professor of Obstetrics & Gynecology, University of Cincinnati Cancer Institute, explains the importance of "weights and plates" in ...

video

David Roberge, MD, discusses how COVID-19 affected enrollment in the CE.7 clinical trial

Dr. Roberge, Head of Radiation Oncology, University of Montreal, discusses how COVID-19 affected enrollment in the CE.7 clinical trial, how ...

Related Videos

video-image

Thomas Herzog, MD, explains the importance of "weights and plates" in the PRIMA clinical trial

video-image

David Roberge, MD, discusses how COVID-19 affected enrollment in the CE.7 clinical trial

video-image

Novel Endpoints: Working Through Today's Challenges to Improve the Future of Cancer Care

video-image

Novel Endpoints in Cancer Care: What Lies Ahead

video-image

Oncology Clinical Trials: Why We're Searching for Emerging Endpoints

video-image

Thaddeus Beck, MD, FACP, on how Watson for Clinical Trials Matching can increase practice efficiency

video-image

Thaddeus Beck, MD, FACP, explains how Watson for Clinical Trials Matching operates

video-image

Thaddeus Beck, MD, FACP, shares his experience working with Watson for Clinical Trials Matching

video-image

Debu Tripathy, MD, regarding the results of the MONARCH-2 study

video-image

Debu Tripathy, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

video-image

Jeff Sharman, MD, shares results of the GENUINE phase 2 study presented at ASCO 2017

video-image

Kathryn Kolibaba, MD, shares the results of the MAGNIFY study presented at ASCO

video-image

Mohammad Jahanzeb, MD, FACP, discusses the results of the MONARCH-2 study presented at ASCO

video-image

Mohammad Jahanzeb, MD, FACP, on the impact of the APHINITY study presented at ASCO

video-image

Philip Philip, MD, on the lenvatinib data in patients with unresectable HCC presented at ASCO 2017

video-image

Daniel Petrylak, MD, on prostate cancer guidelines and the results of the LATITUDE study

video-image

Aref Al-Kali, MD, on the data coming out of ASCO 2017 regarding FLT3 mutant AML patients

video-image

Andrew Norden, MD, on how Watson for Clinical Trial Matching (CTM) operates

video-image

Patrick Cobb, MD, on how clinical trials improve care and contribute a revenue stream

video-image

Skip Burris, MD, on the impact of OCM on large community practices

video-image

Lucio Gordan, MD, offers recommendations for practices to improve clinical trial participation

video-image

Bobby Green, MD, on using genomic data to prescreen eligibility for clinical trials

video-image

Alexander Lesokhin, MD provides an update on the CASTOR trial presented at ASCO 2016

video-image

Skip Burris, MD, outlines the scope of cancer clinical trials at SCRI

video-image

Jennifer Carter, MD, MPH, explains how oncology clinical trial design is adopting precision medicine

video-image

Venetoclax Produces Good Responses for 17p Deletion May Be Approved in 2016

video-image

Brian Slomovitz, MD, regarding the long term follow-up data on PARP inhibitors in ovarian cancer

video-image

Brian Slomovitz, MD, elaborates on the role of immunotherapy in ovarian cancer

video-image

Brian Slomovitz, MD, offers opinion on the repeat use of PARP inhibitors

video-image

Brian Slomovitz, MD, on incorporating biomarker-driven therapy in ovarian cancer

video-image

BJ Rimel, MD, considers the challenges associated with genetic counseling

video-image

BJ Rimel, MD, provides opinion on genetic counseling as a standard operating procedure

video-image

BJ Rimel, MD, regarding the MAGENTA study and the role of genetic counseling

video-image

Robert L. Coleman, MD, FACOG, FACS, shares his impressions of the SOLO-1 update from ESMO 2020

video-image

Robert L. Coleman, MD, FACOG, FACS, on the role of HRD in the management of ovarian cancer

video-image

Robert L. Coleman, MD, FACOG, FACS, tells us about the negative outcomes from the IMagyn050 study

video-image

Thomas Herzog, MD, elaborates on his approach to BRCA and HRD testing

video-image

Thomas Herzog, MD, considers the use of a PARP in a patient that failed first line PARP therapy

video-image

Case Study: High-Grade Serous Ovarian Cancer Recurrence

video-image

Case Study: COVID-19 and Ovarian Cancer

video-image

Case Study: High-Grade Serous Ovarian Cancer Recurrence - Surgery vs. Chemotherapy

video-image

Case Study: Platinum Sensitive Recurrent High-Grade Serous Ovarian Cancer

video-image

Dana Chase, MD, FACOG, shares thoughts on the role of I-O in GTT management

video-image

Dana Chase, MD, FACOG, provides thoughts on the clinical evidence of secondary cytoreductive surgery

video-image

Dana Chase, MD, FACOG, on interpretations of the overall survival results of the Phase 3 SOLO2 study

video-image

Dana Chase, MD, FACOG, summarizes the outcomes of the NRG-GY004 phase III study in ovarian cancer

video-image

Andres Poveda, MD, considers the role of PARP inhibitors in advanced ovarian cancer

video-image

Andres Poveda, MD, discusses the BRCA mutation and homologous recombination deficiency

video-image

Andres Poveda, MD, shares design and outcomes of the PHASE 3 SOLO2 regarding ovarian cancer

video-image

Dana Chase, MD, FACOG, considers the role of PARP inhibitors in advanced ovarian cancer today

video-image

Dana Chase, MD, FACOG, shares details about PRIMA and PAOLA clinical studies regarding ovarian cancer

video-image

Joyce Liu, MD, provides perspective on the large studies in advanced ovarian cancer

video-image

Joyce Liu, MD, on overall survival outcomes of Phase 3 SOLO2 study regarding advanced ovarian cancer

video-image

Joyce Liu, MD, shares thoughts on the activity of the Wee1 inhibitor as monotherapy in USC

video-image

Joyce Liu, MD, provides good news, in spite of Phase 3 NRG-GY004 study being negative

video-image

Joyce Liu, MD, summarizes the outcomes of the NRG-GY004 phase III study regarding ovarian cancer

video-image

Joyce Liu, MD, provides background and design of the NRG-GY004 phase III study regarding ovarian cancer

video-image

Robert Coleman, MD, FACOG, FACS, describes the overall survival outcomes of the Phase 3 SOLO2 clinical study

video-image

Robert Coleman, MD, FACOG, FACS, explains the underlying biology of homologous recombination deficiency

video-image

Robert Coleman, MD, FACOG, FACS, discusses the 2 recent FDA approvals for PARP inhibitors in ovarian cancer

video-image

Robert Coleman, MD, FACOG, FACS, provides thoughts on the NRG-GY004 phase III study

video-image

Robert Coleman, MD, FACOG, FACS, shares conclusions that can be drawn from phase 3 GOG213 study at ASCO20

video-image

Karen Lu, MD, discusses how PARP inhibitors have changed the management of advanced ovarian cancer

video-image

Karen Lu, MD, illustrates challenges the MAGENTA study brings up associated with genetic counseling

video-image

Karen Lu, MD, provides opinion on whether genetic counseling should be part of the SOP for breast and ovarian cancer risk

video-image

Karen Lu, MD, shares outcomes of the MAGENTA study investigating the role of genetic counseling

video-image

Karen Lu MD, elaborates on the underlying biology of homologous recombination deficiency (HRD) and how it applies to ovarian cancer management

video-image

Robert L. Coleman, MD, FACOG, FACS, on takeaways from the ovarian plenary session at ESMO '19

video-image

Robert L. Coleman, MD, FACOG, FACS, on how veliparib factors into ovarian cancer treatment

video-image

David Gershenson, MD, on considerations for maintenance therapy in ovarian cancer

video-image

David Gershenson, MD, elaborates on the role of MEK inhibitor trametinib in LGSC

video-image

Michael J. Birrer, MD, PhD, considers the benefits of various PARP inhibitors in ovarian cancer

video-image

Michael J. Birrer, MD, PhD, regarding BRCA status in newly diagnosed ovarian cancer

video-image

Michael J. Birrer, MD, PhD, on the role of maintenance therapy in newly diagnosed ovarian cancer

video-image

Michael J. Birrer, MD, PhD, elaborates on the outcomes from the FORWARD I study

video-image

Michael Birrer, MD, on the key takeaways from the ovarian plenary session in ovarian cancer at ESMO 2019

video-image

Joanie Mayer Hope, MD, on how Any Mountain is supporting women with ovarian cancer